Therapeutic modulation of cytokines in chronic infectious diseases

Current Pharmaceutical Design

Volumn 12, Issue 19, 2006, Pages 2329-2348

  Villar, C C ^a   Dongari Bagtzoglou, A ^a  

^a UNIVERSITY OF CONNECTICUT   (United States)

Author keywords

Fungal infections; Humoral immunity; Klebsiella Pneumoniae infection; Listeriosis; Lyme disease; NK cell proliferation; Proinflammatory

Indexed keywords

ALPHA1 INTERFERON; AMPHOTERICIN B; ANTIFUNGAL AGENT; ANTIINFECTIVE AGENT; ANTINEOPLASTIC AGENT; BETA INTERFERON; COLONY STIMULATING FACTOR 1; CYTOKINE; DNA VACCINE; FLUCONAZOLE; FOSCARNET; GAMMA INTERFERON; GAMMA1B INTERFERON; GANCICLOVIR; IMMUNOMODULATING AGENT; INTERLEUKIN 11; INTERLEUKIN 12; INTERLEUKIN 15; INTERLEUKIN 1ALPHA; INTERLEUKIN 2; INTERLEUKIN 4; PLACEBO; PYRROLE DERIVATIVE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; RECOMBINANT INTERLEUKIN 12; RECOMBINANT INTERLEUKIN 18; RECOMBINANT TUMOR NECROSIS FACTOR ALPHA; TUBERCULOSTATIC AGENT; UNINDEXED DRUG;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANTIINFLAMMATORY ACTIVITY; ASPERGILLOSIS; BACTERIAL INFECTION; CANCER PATIENT; CANDIDIASIS; CELLULAR IMMUNITY; CLINICAL TRIAL; CRYPTOCOCCOSIS; CYTOMEGALOVIRUS INFECTION; DRUG POTENTIATION; GRAFT RECIPIENT; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C; HEPATITIS C VIRUS; HISTOPLASMOSIS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMORAL IMMUNITY; IMMUNE DEFICIENCY; IMMUNOSUPPRESSIVE TREATMENT; IMMUNOTHERAPY; INCIDENCE; INFECTION CONTROL; KLEBSIELLA PNEUMONIAE; LEISHMANIASIS; LISTERIOSIS; LUNG INFECTION; LYME DISEASE; MACROPHAGE ACTIVATION; MALARIA; MONOTHERAPY; MYCOSIS; NEUTROPENIA; NONHUMAN; OPPORTUNISTIC INFECTION; PARASITOSIS; PERSISTENT INFECTION; PNEUMONIA; PRIORITY JOURNAL; PROTEIN FUNCTION; REVIEW; SIGNAL TRANSDUCTION; SYSTEMATIC REVIEW; T LYMPHOCYTE ACTIVATION; TUBERCULOSIS; VIRUS INFECTION;

ANIMALS; BACTERIAL INFECTIONS; CHRONIC DISEASE; CLINICAL TRIALS; COMMUNICABLE DISEASES; CYTOKINES; DISEASE MODELS, ANIMAL; HUMANS; VIRUS DISEASES;

EID: 33745755627     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161206777698981     Document Type: Review

References (229)

1. Bisno AL. Cutaneous infections: microbiologic and epidemiologic considerations. Am J Med 1984; 76(5A): 172-9.
2. Johansen FE, Brandtzaeg P. Transcriptional regulation of the mucosal IgA system. Trends in Immunol 2004; 25(3): 150-7.
3. McNeela EA, Mills KHG. Manipulating the immune system: humoral versus cell-mediated immunity. Adv Drug Deliv Rev 2001; 51(1-3):43-54.
4. Fidel PL Jr. Distinctive protective host defense against vaginal candidiasis: lessons learned from clinical studies and animal models. Int Rev Immunol 2002; 21: 515-48.
5. Fidel PL Jr, Lynch ME, Sobel JD. Candida-specific Th1-type responsiveness in mice with experimental vaginal candidiasis. Infect Immun 1993; 61(10): 4202-7.
6. Taylor BN, Saavedra M, Fidel PL Jr. Local Th1/Th2 cytoldne production during experimental vaginal candidiasis: potential importance of transforming growth factor-beta. Med Mycol 2000; 38(6): 419-31.
7. Leigh JE, Barousse M, Swoboda RK, Myers T, Hager S, Wolf NA, et al. Candida-specific systemic cell-mediated immune reactivities in human immunodeficiency virus-positive persons with mucosal candidiasis. J Infect Dis 2001; 183: 277-85.
8. Warris A, Bjorneklett A, Gaustad P. Invasive pulmonary aspergillosis associated with infliximab therapy. N Engl J Med 2001; 344(14): 1099-100.
9. Romani L, Bistoni F, Puccetti P. Fungi, dendritic cells and receptors: a host perspective of fungal virulence. Trends Microbiol 2002; 10(11):508-14.
10. Basset C, Holton J, O'Mahony R, Roitt I. Innate immunity and pathogen-host interaction. Vaccine 2003; 21 (Suppl. 2): S12-23.
11. McEver RP, Moore KL, Cummings RD. Leukocyte trafficking mediated by selectin-carbohydrate interactions. J Biol Chem 1995; 270(19): 11025-8.
12. Tosi MF, Hamedani A, Brosovich J, Alpert SE. ICAM-1-independent, CD18-dependent adhesion between neutrophils and human airway epithelial cells exposed in vitro to ozone. J Immunol 1994; 152(4):1935-42.
13. Kapp A, Zeck-Kapp G. Activation of the oxidative metabolism in human polymorphonuclear neutrophilic granulocytes: the role of immuno-modulating cytokines. J Invest Dermatol 1990; 95(6 Suppl): 94S-9S.
14. Ellis M, Gupta S, Galant S, Hakim S, VandenVen C, Toy C, et al. Impaired neutrophil function in patients with AIDS or AIDS-related complex: A comprehensive evaluation. J Infect Dis 1988; 158: 1268-75.
15. Murphy PM, Lane CH, Fauci AS, Gallin JI. Impairement of neutrophil bactericidal capacity in patients with AIDS. J Infect Dis 1988; 158:627-31.
16. Coffey MJ, Phare SM, George S, Peters-Golden M, Kazanjian PH. Granulocyte colony-stimulating factor administration to HIV-infected subjects augments reduced leukotriene synthesis and anticryptococcal activity in neutrophils. J Clin Invest 1998; 102: 663-70.
17. Roilides E, Mertins S, Eddy J, Walsh TJ, Pizzo PA, Rubin M. Imapairement of neutrophil chemotactic and bactericidal function in children infected with HIV type 1 and partial reversal after in vitro exposure to GM-CSF. J Pediatr 1990; 117: 531-40.
18. Pitrak DL, Bak PM, DeMarais P, Novak RM, Andersen BR. Depressed neutrophil superoxide production in HIV infection. J Infect Dis 1993; 167: 1406-10.
19. Meyer CN, Nielsen H. Priming of neutrophil and monocyte activation in HIV infection. APMIS 1996; 104: 640-6.
20. Adams DO, Hamilton TA. The cell biology of macrophage activation. Annual Review of Immunology 1984; 2: 283-318.
21. Ma J, Cgen T, Mandelin J, Ceponis A, Miller NE, Hukkanen M, et al. Regulation of macrophage activation. Cell Mol Life Sci 2003; 60(11): 2334-46.
22. Denis M. Involvement of cytokines in determining resistance and acquired immunity in murine tuberculosis. J Leuk Biol 1991; 50: 495-501.
23. Kindler V, Grau GE, Vassalli P. The inducing role of tumor necrosis factor in the development of bacterial granulomas during BCG infection. Cell 1989; 56: 731-40.
24. Takashima T, Veta C, Tsuyuguchi I, Kishimoto S. Production of tumor necrosis factor alpha by monocytes from patients with pulmonary tuberculosis. Infect Immun 1990; 58: 3286-92.
25. Jouanguy E, Doffinger R, Dupuis S, Pallier A, Altare F, Casanova JL. IL-12 and IFN-gamma in host defense against mycobacteria and salmonella in mice and men. Curr Opin Immunol 1999; 11(3): 346-51.
26. Atherton SS, Newell CK, Kanter MY, Cousins SW. T cell depletion increases susceptibility to murine cytomegalovirus retinitis. Invest Ophthalmol Vis Sci 1992; 33(12): 3353-60.
27. Tarleton RL, Koller BH, Latour A, Postan M. Susceptibility of beta 2-microglobulin-deficient mice to Trypanosoma cruzi infection. Nature 1992; 356(6367): 338-40.
28. Schluns KS, Kieper WC, Jameson SC, Lefrancois L. Interleukin-7 mediates the homeostasis of naive and memory CD8 T cells in vivo. Nat. Immunol 2000: 1(5): 426-32.
29. D'Souza WN, Schluns KS, Masopust D, Lefrancois L. Essential role for IL-2 in the regulation of antiviral extralymphoid CD8 T cell responses. J Immunol 2002; 168: 5566-72.
30. Zou W, Foussa A, Capitant C, Durand-Gasselin I, Bouchet L, Galanaud P, et al. Acute activation of CD8+ T lymphocytes in interleukin-2-treated HIV-infected patients. ANRS-048 IL-2 Study Group. Agence Nationale de Recherches sur le SIDA. J Acquir Immune Defic Syndr 1999; 22(1): 31-8.
31. Schluns KS, Williams K, Ma A, Zheng XX, Lefrancois L. Cutting edge: requirement for IL-15 in the generation of primary and memory antigen-specific CD8 T cells. J. Immunol 2002; 168: 4827-31.
32. Tan JT, Ernst B, Kieper WC, LeRoy E, Sprent J, Surh CD. Interleukin (IL)- 15 and IL-7 jointly regulate homeostatic proliferation of memory phenotype CD8+ cells but are not required for memory phenotype CD4+ cells. J Exp Med 2002; 195: 1523-32.
33. + T cells. J Exp Med 2002; 195: 1515-22
34. Biron CA, Nguyen KB, Pien GC, Cousens LP, Salazar-Mather TP. Natural killer cells in antiviral defense: function and regulation by innate cytokines. Annu Rev Immunol 1999; 17: 189-220.
35. Kennedy MK, Glaccum M, Brown SN, Butz EA, Viney JL, Embers M, et al. Reversible defects in natural killer and memory CD8 T cell lineages in interleukin 15-deficient mice. J Exp Med 2000; 191: 771-80.
36. Mueller YM, Petrovas C, Bojczuk PM, Dimitriou ID, Beer B, Silvera P, et al. Interleukin-15 increases effector memory CD8+ t cells and NK Cells in simian immunodeficiency virus-infected macaques. J Virol 2005; 79(8): 4877-85.
37. Cai G, Kastelein RA, Hunter CA. IL-10 enhances NK cell proliferation, cytotoxicity and production of IFN-gamma when combined with IL-18. Eur J Immunol 1999; 29: 2658-65.
38. O'Shea JJ, Visconti R. Type 1 IFNs and regulation of TH1 responses: enigmas both resolved and emerge. Nat Immunol 2000: 1: 17-9
39. Trinchieri G. Interleukin-12: a proinflammatory cytokine with immunoregulatory functions that bridge innate resistance and antigen-specific adaptive immunity. Annu Rev Immunol 1995; 13: 251-76.
40. Robinson D, Shibuya K, Mui A, Zonin F, Murphy E, Sana T, et al. IGIF does not drive Th1 development but synergizes with IL-12 for interferon-gamma production and activates IRAK and NFkappaB. Immunity 1997; 7: 571-81.
41. Coffman RL, Savelkoul HF, Lehman DA. Cytokine regulation of immunoglobulin isotype switching and expression. Semin Immunol 1989; 1(1): 55-63.
42. Davies J. Inactivation of antibiotics and dissemination of resistance genes. Science 1994; 264: 375-82.
43. Toews GB, Gross GN, Pierce AK. The relationship of inoculum size to lung bacterial clearance and phagocytic cell response in mice. Am Rev Respir Dis 1980; 120: 559-66.
44. Gamble JR, Harlan JM, Klebanoff SJ. Stimulation of the adberence of neutrophils to umbilical vein endothelium by human recombinant tumor necrosis factor. Proc Natl Acad Sci USA 1985; 82: 8667-71.
45. Le J, Vilcek J. Tumor necrosis factor and interleukin- 1: Cytokines with multiple overlapping biological activities. Lab Invest 1987; 56: 234-48.
46. Tan AM, Ferrante A, Goh DH, Robertson DM, Cripps AW. Activation of the neutrophil bactericidal activity for non typeable Haemophilus influenza by tumor necrosis factor and lymphotoxin. Pediatr Res 1995; 37: 155-9.
47. Standiford TJ, Wilkowski JM, Sisson TH, Hattori N, Mebrad B, Bucknell KA, et al. Intrapulmonary tumor necrosis factor gene therapy increases bacterial clearance and survival in murine gramnegative bacterial pneumonia. Hum Gene Ther 1999; 10: 899-09.
48. Lira SA, Zalamea P, Heinrich JN, Fuentes ME, Carrasco D, Lewin AC, et al. Expression of the chemokine N51/KC in the thymus and epidermis of transgenic mice results in marked infiltration of a single class of inflammatory cells. J Exp Med 1994; 180(6): 2039-48.
49. Frevert CW, Huang S, Danaee H, Paulauskis JD, Kobzik L. Functional characterization of the rat chemokine KC and its importance in neutrophil recruitment in a rat model of pulmonary inflammation. J Immunol 1995: 154: 335-44.
50. Tsai WC, Strieter RM, Wilkowski JM, Bucknell KA, Burdick MD, Lira SA, et al. Lung-specific transgenic expression of KC enhances resistance to Klebsiella pneumoniae in mice. J Immunol 1998; 61: 2435-40.
51. Tripp CS, Unanue ER. Macrophage production of IL-12 is a critical link between the innate and specific immune responses to Listeria. Res Immunol 1995; 146: 515-19.
52. Chan SH, Perussia B, Gupta JW, Kobayashi M, Pospisil HA, Young HA, et al. Induction of interferon-g production by natural killer cell stimulatory factor: Characterization of the responder cells and synergy with other inducers. J Exp Med 1991; 173: 869-79.
53. Trinchieri G. Interleukin-12: A cytokine produced by antigen-presenting cells with immunoregulatory functions in the generation of T-helper cell type 1 and cytotoxic lymphocytes. Blood 1994; 84: 4008-27.
54. Trinchieri G. Interleukin-12: A proinflammatory cytokine with immmunoregulatory functions that bridge innate resistance and antigen-specific adaptive immunity. Annu Rev Immunol 1995; 13: 251-76.
55. Greenberger MJ, Kunkel SL, Strieter RM, Lukacs N, Bramson J, Gauldie J, et al. IL-12 gene therapy protects mice in lethal Klebsiella pneumonia. J Immunol 1996; 157: 3006-12.
56. Southwick FS, Purich DL. Intracellular pathogenesis of listeriosis. N Engl J Med 1996; 334(12): 770-6.
57. Edelson BT, Unanue ER. Immunity to Listeria infection. Curr Opin Immunol 2000; 12(4): 425-31.
58. Gallin JI, Farber JM, Holland SM, Nutman TB. Interferon-γ in the management of infectious diseases. Ann Int Med 1995; 123: 216-24.
59. Murray HW. Interferon-gamma and host antimicrobial defense: current and future clinical applications. Am J Med 1994; 97: 459-67.
60. Torrico F, Heremans H, Rivera MT, Van Marck E, Billiau A, Carrier Y. Endogenous IFN-γ is required for resistance to acute Try-panosoma cruzii infection in mice. J Immunol 1991; 146: 3626-32.
61. Steinmuller C, Franke-Ullmann G, Lohmann-Matthes ML, Emmendorffer A. Local activation of nonspecific defense against a respiratory model infection by application of interferon-gamma: comparison between rat alveolar and interstitial lung macrophages. Am J Respir Cell Mol Biol 2000; 22(4): 481-90.
62. Serushago BA, Yoshikai Y, Handa, T, Mitsuyama M, Muramori K, Nomoto K. Effect of recombinant human granulocyte colony-stimulating factor (rh G-CSF) on murine resistance against Listeria monocytogenes. Immunology 1992; 75(3): 475-80.
63. Kayashima S, Tsuru S, Hata N, Rokutanda M. Therapeutic effect of granulocyte colony-stimulating factor (G-CSF) on the protection against Listeria infection in SCID mice. Immunology 1993; 80(3): 471-6.
64. Buisman AM, Langermans JA, van Furth R. Effect of granulocyte colony-stimulating factor on the course of infection with gram-positive bacteria in mice during granulocytopenia induced by sublethal irradiation or cyclophosphamide. J Infect Dis 1996; 174(2): 417-21.
65. Dale DC, Liles WC, Summer WR, Nelson S. Granulocyte colony-stimulating factor (G-CSF): roles and relationships in infectious diseases. J Infect Dis 1995; 172: 1061-75.
66. Buisman AM, Langermans JA, van Furth R. Effect of granulocyte-macrophage colony-stimulating factor on the number of leucocytes and course of Listeria monocytogenes infection in naive and leucocytopenic mice. Immunology 1998; 93(1): 73-9
67. Richardson MD, Brownlie CE, Shankland GS. Enhanced phagocytosis and intracellular killing of Candida albicans by GM-CSF activated human neutrophils. J Med Vet Mycol 1992; 30: 433-41.
68. Wagner RD, Steinberg H, Brown JF, Czuprynski CJ. Recombinant interleukin-12 enhances resistance of mice to Listeria monocytogenes infection. Microb Pathog 1994; 17(3): 175-86.
69. Kishikawa H, Song R, Lawrence DA. Interleukin-12 promotes enhanced resistance to Listeria monocytogenes infection of lead-exposed mice. Toxicol Appl Pharmacol. 1997: 147(2): 180-9.
70. Desiderio JV, Kiener PA, Lin PF, Warr GA. Protection of mice against Listeria monocytogenes infection by recombinant human tumor necrosis factor alpha. Infect Immun 1989; 57(5): 1615-7.
71. Berkow RL, Wang D, Larrick JW, Dodson RW, Howard TH. Enhancement of neutrophil superoxide production by preincubation with recombinant human tumor necrosis factor. J Immunol 1987; 139: 3783-91.
72. Cannistra SA, Vellenga E, Groshek P, Rambaldi A, Griffin JD. Human granulocyte-monocyte colony-stimulating factor and interleukin 3 stimulate monocyte cytotoxicity through a tumor necrosis factor-dependent mechanism. Blood 1988; 71: 672-6.
73. Clark IA, Hunt NH, Butcher GA, Cowde WB. Inhibition of murine malaria (Plasmodium chabaudi) in vivo by recombinant interferon--y or tumor necrosis factor, and its enhancement by butylated hydroxyanisole. J Immunol 1987; 139: 3493-6.
74. Roll JT, Young KM, Kurtz RS, Czuprynski CJ. Human rTNF alpha augments anti-bacterial resistance in mice: potentiation of its effects by recombinant human rIL-1 alpha. Immunology 1990; 69(2): 316-22.
75. Steere AC, Grodzicki RL, Kornblatt AN, Craft JE, Barbour AG, Burgdorfer W, et al. The spirochetal etiology of Lyme disease. N Engl J Med 1983; 308(13): 733-40.
76. Baranton G, Postic D, Saint Girons I, Boerlin P, Piffaretti JC, et al. Delineation of Borrelia burgdorferi sensu stricto, Borrelia garinii sp. nov., and group VS461 associated with Lyme borreliosis. Int J Syst Bacteriol 1992; 42(3): 378-83.
77. Fikrig E, Telford SR 3rd, Barthold SW, Kantor FS, Spielman A, Flavell RA. Elimination of Borrelia burgdorferi from vector ticks feeding on OspA-immunized mice. Proc Natl Acad Sci USA 1992; 89(12): 5418-21.
78. Keane-Myers A, Maliszewski CR, Finkelman FD, Nickell SP. Recombinant IL-4 treatment augments resistance to Borrelia burgdorferi infections in both normal susceptible and antibody-deficient susceptible mice. J Immunol 1996; 156(7): 2488-94.
79. Keane-Myers A, Nickell SP. Role of IL-4 and IFN-γ in modulation of immunity to Borrelia burgdorferi in mice. J Immunol 1995; 155: 2020-8.
80. Anguita J, Barthold SW, Samanta S, Ryan J, Fikrig E. Selective anti-inflammatory action of interleukin-11 in murine Lyme disease: arthritis decreases while carditis persists. J Infect Dis 1999; 179(3): 734-7.
81. Barthold SW, Beck DS, Hansen GM, Terwilliger GA, Moody KD. Lyme borreliosis in selected strains and ages of laboratory mice. J Infect Dis 1990; 162: 133-138.
82. Ruderman EM, Kerr JS, Telford SR, Spielman A, Glimcher LH, Gravallese EM. Early murine Lyme carditis has a macrophage predominance and is independent of major histocompatibility complex class II-CD4+ T cell interactions. J Infect Dis 1995; 171: 362-70.
83. WHO, Global tuberculosis control: surveillance, planning, financing, WHO, Geneva 2004.
84. Espinal MA, Laszlo A, Simonsen L, Boulahbal F, Kim SJ, Reniero A, et al. Global trends in resistance to antituberculosis drugs. N Engl J Med 2001; 344: 1294-303.
85. Johnson BJ, Ress SR, Willcox P, Pati BP, Lorgat F, Stead P, et al. Clinical and immune responses of tuberculosis patients treated with low-dose IL-2 and multidrug therapy. Cytokines Mol Ther 1995; 1: 185-96.
86. Johnson BJ, Bekker LG, Rickman R, Brown S, Lesser M, Ress S, et al. rhuIL-2 adjunctive therapy in multidrug resistant tuberculosis: a comparison of two treatment regimens and placebo. Tuber Lung Dis 1997; 78: 195-203.
87. Johnson JL, Ssekasanvu E, Okwera A, Mayanja H, Hirsch CS, Nakibali JG, et al. Randomized trial of adjunctive interleukin-2 in adults with pulmonary tuberculosis. Am J Respir Crit Care Med 2003; 168(2): 185-91.
88. Lalvani A. CD8 cytotoxic T cells and the development of new tuberculosis vaccines. Am J Respir Crit Care Med 2002; 166: 789-90.
89. Lazarevic V, Flynn J. CD8(+) T cells in tuberculosis. Am J Respir Crit Care Med 2002; 166: 1116-21.
90. Lewinsohn DA, Lines RA, Lewinsohn DM. Human dendritic cells presenting adenovirally expressed antigen elicit Mycobacterium tuberculosis-specific CD8+ T cells. Am J Respir Crit Care Med 2002; 166: 843-8.
91. Pedral-Sampaio DB, Netto EM, Brites C, Bandeira AC, Guerra C, Barberin MG, et al. Use of Rhu-GM-CSF in pulmonary tuberculosis patients: results of a randomized clinical trial. Braz J Infect Dis 2003; 7(4): 245-52.
92. Dalton DK, Pitts-Meek S, Keshav S, Figari IS, Bradley A, Stewart TA. Multiple defects of immune cell function in mice with disrupted γ-interferon genes. Science 1993; 259: 1739-42.
93. Huang S, Hendriks W, Althage A, Hemmi S, Bluethmann H, Kamijo R, et al. Immune response in mice that lack the interferon-gamma receptor. Science 1993; 259 (5102): 1742-5.
94. Chan J, Tanaka K, Carroll D, Flynn J, Bloom BR. Effects of nitric oxide synthase inhibitors on murine infection with Mycobacterium. tuberculosis. Infect Immun 1995; 63: 736-40.
95. Kamijo R, Harada H, Matsuyama T, Bosland M, Gerecitano J, Shapiro D, et al. Requirement for transcription factor IRF-1 in NO synthase induction in macrophages, Science 1994; 263: 1612-5
96. Condos R, Rom WN, Schluger NW. Treatment of multidrug-resistant pulmonary tuberculosis with interferon-gamma via aerosol. Lancet 1997; 349(9064): 1513-5.
97. Umemura M, Nishimura H, Hirose K, Matsuguchi T, Yoshikai Y. Overexpression of IL-15 in vivo enhances protection against Mycobacterium bovis bacillus Calmette-Guerin infection via augmentation of NK and T cytotoxic 1 responses. J Immunol 2001: 167(2): 946-56.
98. Umemura M, Nishimura H, Saito K, Yajima T, Matsuzaki G, Mizuno S, et al. Molecular Interleukin-15 as an immune adjuvant to increase the efficacy of Mycobacterium bovis bacillus Calmette-Guerin vaccination. Infect Immun 2003; 71(10): 6045-8.
99. Kinjo Y, Kawakami K, Uezu K, Yara S, Miyagi K, Koguchi Y, et al. Contribution of IL-18 to Th1 response and host defense against infection by Mycobacterium tuberculosis: a comparative study with IL-12p4O. J Immunol 2002; 169(1): 323-9.
100. Nolt D, Flynn JL. Interleukin-12 therapy reduces the number of immune cells and pathology in lungs of mice infected with Mycobacterium tuberculosis. Infect Immun 2004; 72(5): 2976-88.
101. Martin E, Kamath AT, Briscoe H, Britton WJ. The combination of plasmid interleukin-12 with a single DNA vaccine is more effective than Mycobacterium bovis (bacille Calmette-Guerin) in protecting against systemic Mycobacterim avium infection. Immunology 2003; 109(2): 308-14.
102. Greinert U, Ernst M, Schlaak M, Entzian P. Interleukin-12 as successful adjuvant in tuberculosis treatment. Eur Respir J 2001; 17: 1049-51.
103. Gerson SL, Talbot GH, Hurwitz S, Strom BL, Lusk EJ, Cassileth PA. Prolonged granulocytopenia: the major risk factor for invasive pulmonary aspergillosis in patients with acute leukemia. Ann Intern Med 1984; 100: 345-51.
104. Latgé JP. Aspergillus fumigatus and aspergillosis. Clin Microbiol Rev 1999; 12: 310-50.
105. Schaffner A, Douglas H, Braude A. Selective protection against conidia by mononuclear and against mycelia by polymorphonuclear phagocytes in resistance to Aspergillus: observations on these two lines of defense in vivo and in vitro with human and mouse phagocytes. J Clin Invest 1982; 69: 617-31.
106. Levitz SM, Diamond RD. Mechanisms of resistance of Aspergillus fumigatus conidia to killing by neutrophils in vitro. J Infect Dis 1985; 152: 33-42.
107. Gonzalez CE, Lyman CA, Lee S, Del Guercio C, Roilides E, Bacher J, et al. Recombinant human macrophage colony-stimulating factor augments pulmonary host defences against Aspergillus fumigatus. Cytokine 2001; 15(2): 87-95.
108. Cenci E, Mencacci A, Fe d'Ostiani C, De Sero G, Mosci P, Montagnoli C, et al. Cytokine- and T helper-dependent lung mucosal immunity in mice with invasive pulmonary aspergillosis. J Infect Dis 1998; 178(6): 1750-60.
109. Sionov E, Segal E. Polyene and cytokine treatment of experimental aspergillosis. FEMS Immunol Med Microbiol 2003; 39(3): 221-7.
110. Mehrad B, Wiekowski M, Morrison BE, Chen SC, Coronel EC, Manfra DJ, et al. Transient lung-specific expression of the chemokine KC improves outcome in invasive aspergillosis. Am J Respir Crit Care Med 2002; 166(9): 1263-8.
111. Rubin RH. Fungal and bacterial infections in the immunocompromised host. Eur J Clin Microbiol Infect Dis 1993; 12 (Suppl.): S42-8.
112. Kullberg BJ, Netea MG, Curfs JH, Keuter M, Meis JF, Van der Meer JW. Recombinant murine granulocyte colony-stimulating factor protects against acute disseminated Candida albicans infection in nonneutropenic mice. J Infect Dis 1998; 177: 175-81.
113. Herbrecht R, Waller J, Koenig H, Morier P, Letscher V. Synergistic efficacy of recombinant human granulocyte colony-stimulating factor and amphotericin B against disseminated candidosis in non neutropenic mice. J Myco Med 1996; 6: 43-8.
114. Vonk AG, Netea MG, van Krieken JH, Verweij PE, van der Meer JW, Kullberg BJ. Treatment of intra-abdominal abscesses caused by Candida albicans with antifungal agents and recombinant murine granulocyte colony-stimulating factor. Antimicrob Agents Chemother 2003; 47(12): 3688-93.
115. Kullberg BJ, Netea MG, Vonk AG, van der Meer JW. Modulation of neutrophil function in host defense against disseminated Candida albicans infection in mice. FEMS Immunol Med Microbiol 1999; 26: 299-07.
116. Hamood M, Bluche PF, De Vroey C, Corazza F, Bujan W, Fondu P. Effects of recombinant human granulocyte-colony stimulating factor on neutropenic mice infected with Candida albicans: acceleration of recovery from neutropenia and potentiation of anti-C. albicans resistance. Mycoses 1994; 37(3-4): 93-9.
117. Uchida K, Yamamoto Y, Klein TW, Friedman H, Yamaguchi H. Granulocyte-colony stimulating factor facilitates the restoration of resistance to opportunistic fungi in leukopenic mice. J Med Vet Mycol 1992; 30(4): 293-300.
118. Mayer P, Schutze E, Lam C, Kricek F, Liehl E. Recombinant murine granulocyte-macrophage colony-stimulating factor augments neutrophil recovery and enhances resistance to infections in myelosuppressed mice. J Infect Dis 1991; 3(3): 584-90.
119. Vazquez JA, Gupta S, Villanueva A. Potential utility of recombinant human GM-CSF as adjunctive treatment of refractory oropharyngeal candidiasis in AIDS patients. Eur J Clin Microbiol Infect Dis 1998; 17(11): 781-3.
120. Kuhara T, Uchida K, Yamaguchi H. Therapeutic efficacy of human macrophage colony-stimulating factor, used alone and in combination with antifungal agents, in mice with systemic Candida albicans infection. Antimicrob Agents Chemother 2000; 44(1): 19-23.
121. Vitt CR, Fidler JM, Ando D, Zimmerman RJ, Aukerman SL. Antifungal activity of recombinant human macrophage colony-stimulating factor in models of acute and chronic candidiasis in the rat. J Infect Dis 1994; 169(2): 369-74.
122. Eng RH, Bishburg E, Smith SM. Cryptococcal infections in patients with acquired immune deficiency syndrome. Am J Med 1986; 81: 19-23.
123. Granger DL, Perfect JR, Durack DT. Macrophage-mediated fungistasis in vitro: requirements for intracellular and extracellular cytotoxicity. J Immunol 1986; 36: 672-80.
124. Hidore MR, Murphy JW. Murine natural killer cell interactions with a fungal target, Cryptococcus neoformans. Infect Immun 1989; 57: 1990-98.
125. Kawakami K, Tohyama M, Teruya K, Kudeken N, Xie Q, Saito A. Contribution of interferon-gamma in protecting mice during pulmonary and disseminated infection with Cryptococcus neoformans. FEMS Immunol Med Microbiol 1996; 13(2): 123-30.
126. Joly V, Saint-Julien E, Carbon C, Yeni P. In vivo activity of interferon-gamma in combination with amphotericin B in the treatment of experimental cryptococcosis. J Infect Dis 1994; 170(5): 1331-4.
127. Lutz JE, Clemons KV, Stevens DA. Enhancement of antifungal chemotherapy by interferon-gamma in experimental systemic cryptococcosis. J Antimicrob Chemother 2000; 46(3): 437-42.
128. Pappas PG, Bustamante B, Ticona E, Hamill RJ, Johnson PC, Reboli A, et al. Recombinant interferon- gamma 1b as adjunctive therapy for AIDS-related acute cryptococcal meningitis. J Infect Dis 2004; 189(12): 2185-91.
129. Netea MG, Brouwer AE, Hoogendorn EH, Van der Meer JW, Koolen M, Verweij PE, et al. Two patients with cryptococcal meningitis and idiopathic CD4 lymphopenia: defective cytokine production and reversal by recombinant interferon- gamma therapy. Clin Infect Dis 2004; 39(9): e83-7.
130. Kawakami K, Qureshi MH, Zhang T, Okamura H, Kurimoto M, Saito A. IL-18 protects mice against pulmonary and disseminated infection with Cryptococcus neoformans by inducing IFN-gamma production. J Immmunol 1997; 159(11): 5528-34.
131. Kawakami K, Tohyama M, Xie Q, Saito A. IL-12 protects mice against pulmonary and disseminated infection caused by Cryptococcus neoformans. Clin Exp Immunol 1996; 104(2): 208-14.
132. Clemons KV, Brummer E, Stevens DA. Cytokine treatment of central nervous system infection: efficacy of interleukin-12 alone and synergy with conventional antifungal therapy in experimental cryptococcosis. Antimicrob Agents Chemother 1994; 3 8(3): 460-4
133. Qureshi MH, Zhang T, Koguchi Y, Nakashima R, Okamura H, Kurimoto M, et al. Combined effects of IL-12 and IL-18 on the clinical course and local cytokine production in murine pulmonary infection with Cryptococcus neoformans. Eur J Immunol 1999; 29(2): 643-9.
134. Graybill JR, Bocanegra R, Lambros C, Luther MF. Granulocyte colony stimulating factor therapy of experimental cryptococcal meningitis. J Med Vet Mycol 1997; 35(4): 243-7.
135. Deepe GS Jr. In: Mandell GL, Bennett JE, Dolm R Ed, Principles and practices of infectious diseases. Philadelphia, Churchill Living-stone 2000; 2718-33.
136. Allendörfer-Fernandez R, Brunner GD, Deepe GS Jr. Complex requirements for nascent and secondary immunity in pulmonary histoplasmosis. J Immunol 1999; 162: 7389-96
137. Kurowski R, Ostapchuk M. Overview of histoplasmosis. Am Fam Physician 2002; 66(12): 2247-52.
138. Powderly WG. Cryptococcal meningitis and AIDS. Clin Infect Dis 1993; 17(5): 837-42.
139. Clemons KV, Lutz JE, Stevens DA. Efficacy of interferon-gamma and amphotericin B for the treatment of systemic murine histoplasmosis. Microbes Infect 2001; 3(1): 3-10
140. Deepe GS Jr, Gibbons R. Recombinant murine granulocyte-macrophage colony-stimulating factor modulates the course of pulmonary histoplasmosis in immunocompetent and immunodeficient mice. Antimicrob Agents Chemother 2000; 44(12): 3328-36.
141. Zhou P, Sieve MC, Bennett J, Kwon-Chung KJ, Tewari RP, Gazzinelli RT, et al. IL-12 prevents mortality in mice infected with Histoplasma capsulatum through induction of IFN-gamma. J Immunol 19951; 155(2):785-95.
142. Cheung TW, Teich SA. Cytomegalovirus infection in patients with HIV infection. Mt Sinai J Med 1999; 66(2): 113-24.
143. Reed EC, Meyers JD. Treatment of cytomegalovirus infection. Clin Lab Med 1987; 7(4): 831-52.
144. Loenen WA, Bruggeman CA, Wiertz EJ. Immune evasion by human cytomegalovirus: lessons in immunology and cell biology. Semin Immunol 2001; 13(1): 41-9.
145. Miller DM, Zhang Y, Rahill BM, Waldman WJ, Sedmak DD. Human cytomegalovirus inhibits IFN-alpha-stimulated antiviral and immunoregulatory responses by blocking multiple levels of IFN-alpha signal transduction. J Immunol. 1999; 162(10): 6107-13
146. Harle P, Noisakran S, Carr DJ. The application of a plasmid DNA encoding IFN-alpha 1 postinfection enhances cumulative survival of herpes simplex virus type 2 vaginally infected mice. J Immunol 2001; 166(3):1803-12.
147. Biron CA. Interferons alpha and beta as immune regulators--a new look. Immunity 2001; 14(6): 661-4.
148. Tough DF, Borrow P, Sprent J. Induction of bystander T cell proliferation by viruses and type I IFN in vivo. Science 1996; 272: 1947-50.
149. Bartlett EJ, Cull VC, Mowe EN, Mansfield JP, James CM. Optimization of Naked DNA Delivery for Interferon Subtype Immunotherapy in Cytomegalovirus Infection. Biol Proced Online 2003; 5: 43-52.
150. Dix RD, Cousins SW. Interleukin-2 immunotherapy of murine cytomegalovirus retinitis during MAIDS correlates with increased intraocular CD8+ T-cell infiltration. Ophthalmic Res 2003; 35(3): 154-9.
151. Lowder CY, Butler CP, Dodds EM, Secic M, Recillas-Gispert C. CD8+ T lymphocytes and cytomegalovirus retinitis in patients with the acquired immunodeficiency syndrome. Am J Ophthalmol 1995; 120: 283-90.
152. Tay-Kearney M-L, Enger C, Smeba RD, Royal W III, Dunn JP, Jabs DA. T cell subsets and cytomegalovirus retinitis in human immunodeficiency virus-infected patients. J Infect Dis 1997; 176: 790-4.
153. Wong JB, Koff RS, Tine F, Pauker SG. Cost-effectiveness of interferon-alpha 2b treatment for hepatitis B e antigen-positive chronic hepatitis B. Ann Intern Med 1995; 122(9): 664-75.
154. Kenny-Walsh E. Clinical outcomes after hepatitis C infection from contaminated anti-D immune globulin. N Engl J Med 1999; 340: 1228-33.
155. Di-Bisceglie AM. Natural history of hepatitis C: its impact on clinical management. Hepatology 2000; 31: 1014-8.
156. Somsouk M, Lauer GM, Casson D, Terella A, Day CL, Walker BD, et al. Spontaneous resolution of chronic hepatitis C virus after withdrawal of immunosuppression. Gastroenterology 2003; 124: 1946-9.
157. National Institutes of Health. National Institutes of Health consensus development conference statement management of hepatitis C. Hepatology 2002; 36(5 Suppl 1): S3-20.
158. Lin OS, Keeffe EB. Current treatment strategies for chronic hepatitis B and C. Annu Rev Med 2001; 52: 29-49.
159. Nelson DR, Lauwers GY, Lau JY, Davis G. Interleukin 10 treatment reduces fibrosis in patients with chronic hepatitis C: a pilot trial of interferon nonresponders. Gastroenterology 2000; 118(4): 655-60.
160. Torriani FJ, Rodriguez-Torres M, Rockstroh JK, Lissen E, Gonzalez-García J, Lazzarin A, et al. APRICOT Study Group. Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C vinis infection in HIV-infected patients. N Engl J Med 2004; 351(5): 438-50.
161. Zunich KM, Lane HC. Immunologic abnormalities in HIV infection. Hematol Oncol Clin North Am 1991; 5(2): 215-28.
162. Hammer SM, Squires KE, Hughes MD, Grimes JM, Demeter LM, Currier JS. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team. N Engl J Med 1997; 337: 725-33.
163. Furtado MR, Callaway DS, Phair JP, Kunstman KJ, Stanton JL, Macken CA, et al. Persistence of HIV-1 transcription in peripheral-blood mononuclear cells in patients receiving potent antiretroviral therapy. N Engl J Med 1999; 340(21): 1614-22.
164. De Jong MD, de Boer RJ, de Wolf F, Foudraine NA, Boucher CA, Goudsmit J, et al. Overshoot of HIV-1 viraemia after early discontinuation of antiretroviral treatment. AIDS 1997; 11 (11): F79-84.
165. Kovacs JA, Baseler M, Dewar RJ, Vogel S, Davey RT Jr, Falloon J, et al. Increases in CD4 T lymphocytes with intermittent courses of interleukin-2 in patients with human immunodeficiency virus infection. N Engl J Med 1995; 332: 567-75.
166. Kovacs JA, Vogel S, Albert JM, Falloon J, Davey RT Jr, Walker RE, et al. Controlled trial of interleukin-2 infusions in patients with the human immunodeficiency virus. N Engl J Med 1996; 335: 1350-56.
167. Davey RT Jr, Chaitt DG, Piscitelli SC, Wells M, Kovacs JA, Walker RE, et al. Subcutaneous administration of interleukin-2 in human immunodeficiency virus type 1-infected persons. J Infect Dis 1997; 175: 781-9.
168. Davey RT Jr, Chaitt DG, Albert JM, Piscetelli SC, Kovacs JA, Walker RE,
169. Kovacs JA, Imamichi H, Vogel S, Metcalf JA, Dewar RL, Baseler M, et al. Effects of intermittent interleukin-2 therapy on plasma and tissue human immunodeficiency virus levels and quasi-species expression. J Infect Dis 2000; 182(4): 1063-9.
170. Kovacs JA, Vogel S, Metcalf JA, Baseler M, Stevens R, Adelsberger J, et al. Interleukin-2 induced immune effects in human immunodeficiency virus-infected patients receiving intermittent interleukin- 2 immunotherapy. Eur J Immunol 2001; 31: 1351-60.
171. Miller KD, Spooner K, Herpin BR, Rock-Kress D, Metcalf JA, Davey RT Jr, et al. Immunotherapy of HIV-infected patients with intermittent interleukin-2: Effects of cycle frequency and cycle duration on degree of CD4(+) T-lymphocyte expression. Clin Immunol 2001; 99: 30-42.
172. Martinez-Marino B, Shiboski S, Hecht FM, Kahn JO, Levy JA. Interleukin-2 therapy restores CD8 cell non-cytotoxic anti-HIV responses in primary infection subjects receiving HAART. AIDS 2004; 18(15): 1991-9.
173. Walker CM, Moody DJ, Stites DP, Levy JA. CD8+ lymphocytes can control HIV infection in vitro by suppressing virus replication. Science 1986; 234(4783): 1563-6.
174. Levy JA. The importance of the innate immune system in controlling HIV infection and disease. Trends Immunol 2001; 22(6): 312-6.
175. Weissman D, Dybul M, Daucher MB, Davey RT Jr, Walker RE, Kovacs JA. Interleukin-2 up-regulates expression of the human immunodeficiency virus fusion coreceptor CCR5 by CD4+ lymphocytes in vivo. J Infect Dis 2000; 181: 933-8.
176. Folks TM, Clouse KA, Justement J, Rabson A, Duh E, Kehrl JH, et al. Tumor necrosis factor-α induces expression of human immunodeficiency virus in a chronically infected T cell clone. Proc Natl Acad Sci USA 1989; 86: 2365-8.
177. Crowe SM, Lopez A. GM-CSF and its effects on replication of HIV 1 in cells of macrophage lineage. J Leukoc Biol 1997; 62: 41-8.
178. Unutmaz D, Pileri P, Abrignani S. Anti-independent activation of naive and memory resting T cells by a cytokine combination. J Exp Med 1994; 180(3): 1159-64.
179. Chun TW, Engel D, Mizell SB, Ehler LA, Fauci AS. Induction of HIV-1 replication in latently infected CD4+ T cells using a combination of cytokines. J Exp Med 1998; 188(1): 83-91.
180. Chun TW, Engel D, Mizell SB, Hallahan CW, Fischette M, Park S, et al. Effect of interleukin-2 on the pool of latently infected, resting CD4+ T cells in HIV-1 infected patients receiving highly active anti-retroviral therapy. Nat Med 1999; 5: 651-5.
181. Estaquier J, Idziorek T, Zou W, Emilie D, Farber CM, Bourez JM, et al. T helper type 1/T helper type 2 cytokines and T cell death: preventive effect of interleukin 12 on activation-induced and CD95 (FAS/ APO-1)-mediated apoptosis of CD4+ T cells from human immunodeficiency virus-infected persons. J Exp Med 1995; 182: 1759-67.
182. Clerici M, Lucey DR, Berzofsky JA, Pinto LA, Wynn TA, Blatt SP, et al. Restoration of HIV-specific cell-mediated immune responses by interleukin-12 in vitro. Science 1993; 262: 1721-4.
183. Jacobson MA, Hardy D, Connick E, Watson J, DeBruin M. Phase 1 trial of a single dose of recombinant human interleukin-12 in human immunodeficiency virus-infected patients with 100-500 CD4 cells/microL. J Infect Dis 2000; 182(4): 1070-6.
184. de Waal Malefyt R, Abrams J, Bennett B, Figdor CG, de Vries JE. Interleukin 10(IL-10) inhibits cytokine synthesis by human monocytes: an autoregulatory role of IL-10 produced by monocytes. J Exp Med 199 1; 174: 1209-20.
185. Wang P, Wu P, Siegel MI, Egan RW, Billah MM. IL-10 inhibits transcription of cytokine genes in human peripheral blood mononuclear cells. J Immunol 1994; 153: 811-6.
186. Roux-Lombard P, Modoux C, Cruchaud A, Dayer J-M. Purified blood monocytes from HIV 1-infected patients produce high levels of TNFα and IL-1. Clin Immunol Immunopathol 1989; 50: 374-84.
187. Lathey JL, Kanangat S, Rouse BT, Agosti JM, Spector SA. Dysregulation of cytokine expression in monocytes from HIV-positive individuals. J Leukoc Biol 1994; 56: 347-52.
188. Mellors JW, Griffith BP, Ortiz MA, Landry ML, Ryan JL. Tumor necrosis factor-α/cachectin enhances human immunodeficiency virus type 1 replication in primary macrophages. J Infect Dis 1991; 163: 78-82.
189. Weissman D, Poli G, Fauci AS. Interleukin 10 blocks HIV replication in macrophages by inhibiting the autocrine loop of tumor necrosis factor α and interleukin 6 induction of virus. AIDS Res Hum Retroviruses 1994; 10: 1199-206.
190. Tanaka N, Hoshino Y, Gold J, Hoshino S, Martiniuk F, Kurata T, et al. Interleukin-10 induces inhibitory C/EBPbeta through STAT-3 and represses HIV-1 transcription in macrophages. Am J Respir Cell Mol Biol 2005; 3 3(4): 406-11.
191. Angel JB, Jacobson MA, Skolnik PR, Giordano M, Shapiro L, LeBeaut A, et al. A multicenter, randomized, double-blind, placebo-controlled trial of recombinant human interleukin-10 in HIV-infected subjects. AIDS 2000; 14(16): 2503-8.
192. D'Andrea A, Aste-Amezaga M, Valiante NM, Ma X, Kubin M, Trinchieri G. Interleukin 10 (IL-10) inhibits human lymphocyte interferon γ-production by suppressing natural killer cell stimulatory factor/ IL-12 synthesis in accessory cells. J Exp Med 1993; 178: 1041-8.
193. Del Prete G, De Carli M, Almerigogna F, Giudizi MG, Biagiotti R, Romagnani S. Human IL-10 is produced by both type I helper (Th1) and type 2 helper (Th2) T cell clones and inhibits their antigen-specific proliferation and cytokine production. J Immunol 1993; 150: 353-60.
194. Coyle TE. Hematological complications of HIV and AIDS. Med Clin N Am 1997; 81: 449-70.
195. Deuil-Lemaire ML, Gori A, Vittecoq D, Panelatti G, Tharaux F, Palisses R, et al. Lenograstim for the treatment of neutropenia in patients receiving ganciclovir for cytomegalovirus infection: a randomised, placebo-controlled trial in AIDS patients. Eur J Haematol 2000; 65(5): 337-43.
196. Ellis M, Gupta S, Galant S, Hakim S, Vande Ven C, Toy C, et al. Impaired neutrophil function in patients with AIDS or AIDS-related complex: a comprehensive evaluation. J Infect Dis 1988; 158: 1268-76.
197. Frumkin LR. Role of granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor in the treatment of patients with HIV infection. Curr Opin Hematol 1997; 4: 200-6.
198. Kimura S, Matsuda J, Ikematsu S, Miyazono K, Ito A, Nakahata T, et al. Efficacy of rHuGCSF on neutropenia in patients with AIDS. AIDS 1990; 4: 1251-5.
199. Dührsen U, Villeval JL, Boyd J, Kannourakis G, Morstyn G, Metcalf D. Effects of recombinant human granulocyte colony-stimulating factor on hematopoietic progenitor cells in cancer patients. Blood 1988; 72: 2074-81.
200. Nielsen SD, Sorensen TU, Aladdin H, Ersboll AK, Mathiesen L, Ullum H, et al. The effect of long-term treatment with granulocyte colony-stimulating factor on hematopoiesis in HIV-infected individuals. Scand J Immunol 2000; 52(3): 298-303.
201. Langhorne J. The role of CD4+ T cells in the immune response to Plasmodium chabaudi. Parasitol Today 1989, 5: 362-4.
202. Ferreira A, Schofield L, Enea V, Schllekens H, van der Meide P, Collins WE, et al. Inhibition of development of exoerythrocytic forms of malaria parasites by gamma interferon. Science 1986; 232: 881-4.
203. Maheshwari RK, Czarniecki CW, Dutta GP, Puri SK, Dhawan BN, Friedman RM. Recombinant human gamma interferon inhibits simian malaria. Infect Immun 1986; 53: 628-30.
204. Vigário AM, Belnoue E, Cumano A, Marussig M, Miltgen F, Landau I, et al. Inhibition of Plasmodium yoelii blood-stage malaria by interferon alpha through the inhibition of the production of its target cell, the reticulocyte. Blood 2001; 97(12): 3966-71.
205. Sedegah M, Finkelman F, Hoffman SL. Interleukin 12 induction of interferon gamma-dependent protection against malaria. Proc Natl Acad Sci USA 1994; 91: 10700-2.
206. Stevenson MM, Tam MF, Wolf SF, Sher A. IL-12-induced protection against blood-stage Plasmodium chabaudi AS requires IFN-γ and TNF-α and occurs via a nitric oxide-dependent mechanism. J Immunol 1995; 155: 2545-56.
207. Mohan K, Sam H, Stevenson MM. Therapy with a combination of low doses of interleukin 12 and chloroquine completely cures blood-stage malaria, prevents severe anemia, and induces immunity to reinfection. Infect Immun 1999; 67(2): 513-9.
208. Owhasi M, Kirai N, Asami M. Temporary appearance of a circulating granulocyte-macrophage colony-stimulating factor in lethal murine malaria. Southeast Asian J Trop Med Public Health 1996; 27: 530-4.
209. Kumaratilake LM, Ferrante A, Jaeger T, Rzepczyk C. GM-CSF-induced priming of human neutrophils for enhanced phagocytosis and killing of asexual blood-stages of Plasmodium falciparum: synergistic effects of GM-CSF and TNF. Parasite Immunol 1996; 18: 115-23.
210. Riopel J, Tam M, Mohan K, Marino MW, Stevenson MM. Granulocyte-macrophage colony-stimulating factor deficient mice have impaired resistance to blood-stage malaria. Infect Immun 2001; 69: 129-36.
211. Chukwuocha RU, Reyes E, Tokuda S. The in vivo effects of opioid peptides on the murine immune response. Int. J. Immunopharmacol 1994; 16: 205-15.
212. Singh PP, Singh S. Protection of mice from malaria after co-administration of recombinant mouse granulocyte-macrophage colony-stimulatmg factor and methionine-enkephalin. Eur Cytokine Netw 2001; 12: 528-36.
213. Kaur A, Kinhikar AG, Singh PP. Bioimmunotherapy of rodent malaria: co-treatment with recombinant mouse granulocyte-macrophage colony-stimulating factor and an enkephalin fragment peptide Tyr-Gly-Gly. Acta Trop 2004; 91(1): 27-41.
214. Stevenson MM, Ghadirian E. Human recombinant tumor necrosis factor alpha protects susceptible A/J mice against lethal Plasmodium chabaudi AS infection. Infect Immun 1989; 57(12): 3936-9
215. Olivier M, Gregory DJ, Forget G. Subversion mechanisms by which Leishmania parasites can escape the host immune response: a signaling point of view. Clin Microbiol Rev 2005; 18(2): 293-305.
216. Sadick MD, Heinzel FP, Holaday BJ, Pu RT, Dawkins RS, Locksley RM. Cure of murine leishmaniasis with anti-interleukin 4 monoclonal antibody. Evidence for a T cell-dependent, interferon gamma-independent mechanism. J Exp Med 1990; 171: 115-27
217. Ohkusu K, Yoshimoto T, Takeda K, Ogura T, Kashiwamura S, Iwakura Y, et al. Potentiality of interleukin-18 as a useful reagent for the treatment and prevention of Leishmania major infection. Infect Immun 2000; 68: 2449-56.
218. Kawakami K, Koguchi Y, Qureshi MH, Miyazato A, Yara S, Kinjo Y, et al. IL-18 contributes to host resistance against infection with Cryptococcus neoformans in mice with defective IL-12 synthesis through induction of IFN-γ production by NK cells. J Immunol 2000; 165: 941-947.
219. Li Y, Ishii K, Hisaeda H, Hamano S, Zhang M, Nakanishi K, et al. IL-18 gene therapy develops Th1-type immune responses in Leishmania major-infected BALB/c mice: is the effect mediated by he CpG signaling TLR9? Gene Ther 2004; 11(11): 941-8.
220. Hockertz S, Franke G, Paulini I, Lohmann-Matthes ML. Immunotherapy of murine visceral leishmaniasis with murine recombinant interferon-gamma and MTP-PE encapsulated in liposomes. J Interferon Res 1991; 11(3): 177-85
221. Murray HW. Effect of continuous administration of interferon-gamma in experimental visceral leishmaniasis. J Infect Dis 1990; 161(5): 992-4.
222. Murray HW, Cervia JS, Hariprashad J, Taylor AP, Stoeckle MY, Hockman H. Division Effect of granulocyte-macrophage colony-stimulating factor in experimental visceral leishmaniasis. J Clin Invest 1995; 95(3): 1183-92
223. Santos JB, de Jesus AR, Machado PR, Magalhaes A, Salgado K, Carvalho EM, et al. Antimony plus recombinant human granulocyte-macrophage colony-stimulating factor applied topically in low doses enhances healing of cutaneous Leishmaniasis ulcers: a randomized, double-blind, placebo-controlled study. J Infect Dis 2004; 190(10):1793-6.
224. Almeida RP, Brito J, Machado PL, de Jesus AR, Schriefer A, Guimaraes LH, et al. Successful treatment of refractory cutaneous leishmaniasis with gm-csf and antimonials. Am J Trop Med Hyg 2005; 73(1): 79-81.
225. Akuffo H, Kaplan G, Kiessling R, Teklemariam S, Dietz M, MaElrath J, et al. Administration of recombinant interleukin-2 reduces the local parasite load of patients with disseminated cutaneous leishmaniasis. J Infect Dis 1990; 161(4): 775-80.
226. Anderson PM, Hanson DC, Hasz DE, Halet MR, Blazar BF, Ochoa AC. Cytokines in liposomes: preliminary studies with IL-1, IL-2, IL-6, GM-CSF and interferon-gamma. Cytokine 1994; 6(1): 92-10
227. Alfano M, Rizzi C, Corti D, Adduce L, Poli G. Bacterial toxins: potential weapons against HIV infection. Curr Pharm Des 2005; 11(22): 2909-26.
228. Fabris P, Barnes E, Tositti G, Giordani MT, Grasso A, De Lalla F. Therapy of chronic hepatitis C virus infection in HIV co-infected people. Curr Pharm Des 2004; 10(17): 2111-22.
229. Mahady GB. Medicinal plants for the prevention and treatment of bacterial infections. Curr Pharm Des 2005; 11(19): 2405-27.